Search Results for "Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL"

Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL

Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up data

iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL

Obinutuzumab, Ibrutinib, and Venetoclax for CLL (Chronic Lymphocytic Leukemia) Treatment - ASCO 2022

Long Term Follow-Up With Ibrutinib + Venetoclax to Treat Chronic Lymphocytic Leukemia

Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL

5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL

Achieving undetectable MRD with ibrutinib plus venetoclax for CLL

7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL

Combined acalabrutinib treatments for CLL

GLOW: Assessing ibrutinib plus venetoclax in CLL